Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Original Article from The New England Journal of Medicine — Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

  • Results of ZUMA-7, a head to head trial of Axi-Cel vs SOC (chemo followed by auto) was also published in NEJM the same day as ASH. Axi-cel EFS was 8.3 vs. 2 months favoring CAR-T therapy.